Please assess the completion status of the following clinical trial:

Trial Title: Comprehensive Magnetic Resonance of Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Patients age 30-85 referred to the vascular imaging laboratory with documented evidence of peripheral arterial disease (0.4\<ABI\<0.9) 96 Normal healthy subjects ages 30-85~Exclusion Criteria:~Age\<30, \>85~GFR less than 45mL/min based on a serum creatinine drawn within 90 days of the MRI:~Pregnancy Contraindications to a magnetic resonance examination~* Intracranial clips~* Implantable pacemaker and defibrillator~* Cochlear or intraocular implants~* Claustrophobia~* Any metallic implant not listed as magnetic resonance compatible in Shellock F.G ---Pocket Guide to Magnetic Resonance Procedures and Metallic Objects, Update 2000. Lippincott, Williams and Wilkins

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Randomized (Type: EXPERIMENTAL): Patients are imaged at baseline and randomized to Simvistatin 40 mg each night or Simvistatin 40mg/Zetia 10mg each night for 2 years
- Ezetemibe (Type: EXPERIMENTAL): Patients are imaged at baseline and treated with ezetimibe 10mg each night for 2 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).